Latest
China Assets · Parkinson’s Disease
¥84.2 Million, 84 Centers, $328 Million: Hengrui Took a Drug With No Story All the Way to Filing
HRG2010, Hengrui’s carbidopa/levodopa IR/ER capsule for Parkinson’s motor fluctuations, never made the company’s launch forecast or pipeline appendix — yet quietly finished Phase 3 across 84 centers and had its marketing application accepted on August 24, 2026.
China Pharma Majors · Global Asset ReviewSHR-1819 Files for Approval: The Sixth Ticket In
Hengrui’s anti-IL-4Rα antibody has just had its marketing application accepted, with both co-primary endpoints met in Phase 3. But five domestic rivals against the same target are already ahead of it — and the queue ahead holds at least four still under review.
All articles
Large Chinese Pharma21 articles
Adebrelimab: a PD-L1 that "doesn't rely on standing out on its own" — how Hengrui uses it to thicken its portfolio
One Molecule, Two Names, Two Destinies
US$32.5 million in cash, 7.42 million shares What did Hengrui actually keep in BHB-1893?
CSPC's DP303c (enweiqutuozhumab): A commercialization test of "beating the comparator, only to face a stronger rival"
HLX04-O: an ophthalmic bevacizumab that was "licensed out", Henlius's light move in the anti-VEGF red ocean
RMB 84.2 million, 84 sites, US$328 million: Hengrui took a drug with no story all the way to a marketing filing
HRS-7535: when an oral weight-loss drug is packed into a “US shell”, what exactly did Hengrui sell?
HRS-5635: Hengrui bets on the world’s largest hepatitis B market, but both its timing and its posture deserve scrutiny
IBI343: a gastric cancer ADC already “validated globally”, whose real test is its second tumor type
Olatorepatide: how a domestic pharma “built on oncology” turned weight loss into a US$2 billion going-global case study
Ribupatide: a China-originated GLP-1/GIP dual agonist's breakout case study in globalization
SHR-1819 files for approval: the sixth entry ticket
SHR-4640: a "quiet asset" in Hengrui's chronic disease line — can the commercial platform amplify it into the next steady cash card?
SHR-A2009 wins at the PFS interim: in the global HER3 ADC vacuum, Hengrui hands in its answer sheet first
3SBio's SSGJ-611: after 707, how to play the IL-4Rα card
TQB2102: how should a "third-place" asset play its hand?
TQB3454: on track to be China's first domestic IDH1 inhibitor for IDH1-mutant biliary tract cancer — so why won't it be won or lost in the lab?
TQB3909: when a "technically qualified" BCL-2 inhibitor arrives two or three years late
TQH2722 files for approval: 12 days late, and two years late
Tecotabart vedotin: Sino Biopharm has bet on a global first — where is the real exam?
UBT251: selling the world to Novo Nordisk and keeping China for itself — The United Laboratories' "atypical" way of going global
Chinese Biotech14 articles
Afuresertib: an AKT inhibitor that "won its endpoint but lost on position"
BL-M14D1 + atezolizumab: how does a DLL3 ADC that is "cash-rich but treading on others' heels" take on 1L small cell lung cancer?
Ecnoglutide (XW003)
Withdraw, refile, fall behind: the localization trade-off behind eftansomatropin alfa
How did a Chinese bispecific top the global forecast rankings?
Laikangqitamab (LZM012): a strong hand as "China's first dual-target", played into China's most cutthroat autoimmune race
Lerodalcibep: a molecule with "no suspense at all" — why does entering China turn it into a hard problem?
On the same road, a Chinese company has already published its data in NEJM
Rentosertib: A Panoramic Analysis of Its China Development Strategy
Roconkibart: "the fifth domestic entry ticket" How Junshi Biosciences can make its second pillar stand
Supaglutide alfa: holding an "ultra-long-acting" trump card, can Yinnuo Pharma play differentiation in the GLP-1 red ocean?
Asandeutertinib approved: it won the head-to-head, but arrived two years late to its position
The first domestic oral small-molecule GLP-1 to read out a local Chinese Phase 3: how far has VCT220 sold itself?
YL201: the world's only Phase 3 in nasopharyngeal carcinoma
BD Deals & Industry Events7 articles
CSPC and AstraZeneca's Shijiazhuang plant: I could not find the original source for the widely cited terms
CSPC × AstraZeneca Shijiazhuang biologics manufacturing JV (2026-08-05): an in-depth teardown
Keymed's CM512 meets its Phase 2 endpoints: an announcement without numbers, and a selling point already taken
Forty days after Roche dropped a CD19 TCE, it licensed in another CD19/CD79a trispecific
Nine CAR-T Products, Five Years, Three Lanes: From “Can It Be Approved” to “Who Can Deliver”
16 months and 12 months
Eleven months, US$32.5 million turned into US$382.5 million
China-Originated Assets Licensed to MNCs3 articles
One year after the ex-China license GSK paid US$1 billion to buy the licensee outright
The China game behind US$1.25 billion: PF-08634404 (SSGJ-707) China oncology strategy panorama
A China-originated CLDN18.2 ADC licensed to AstraZeneca: gastric cancer Phase 3 "wins OS across the board, stumbles on PFS" — how should the China battle be fought?